Natural killer cells with enhanced viability, proliferation and cytotoxicity following cryopreservation
View Patent ↗The present disclosure generally relates to compositions of NK cells for adoptive transfer. In particular, the disclosure relates to enhancing viability, proliferation and cytotoxicity of feeder-free NK cells following cryopreservation.
1. An isolated population of natural killer (NK) cells that are thawed following cryopreservation and cultured without feeder cells in the presence of a CpG oligodeoxyribonucleotide (ODN) having a sequence identical to SEQ ID NO:1 at a concentration of 3 μg/ml to 24 μg/ml; and IL-12 at a concentration of 1 μg/ml, wherein said NK cells were cultured without feeder cells prior to the cryopreservation.
2. The population of claim 1 wherein the CpG ODN functions as a pathogen associated molecular pattern.
3. The population of claim 1 wherein a period of cryopreservation provides flexibility to a patients receiving an NK cell adoptive transfer therapy.
4. The population of claim 1 wherein a combination of CpG ODN and IL-12 acts synergistically on NK cell viability and cytotoxicity.
5. An isolated population of natural killer (NK) cells that are thawed following cryopreservation and cultured without feeder cells in the presence of a CpG oligodeoxyribonucleotide (ODN) having a sequence identical to SEQ ID NO:1 at a concentration of 3 μg/ml to 24 μg/ml; and IL-12 at a concentration of 1 μg/ml, wherein said NK cells were expanded from peripheral blood mononuclear cells without feeder cells prior to the cryopreservation.
6. The population of claim 5 wherein the CpG ODN functions as a pathogen associated molecular pattern.
7. The population of claim 5 wherein a period of cryopreservation provides flexibility to a patients receiving an NK cell adoptive transfer therapy.
8. The population of claim 5 wherein a combination of CpG ODN and IL-12 acts synergistically on NK cell viability and cytotoxicity.